Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. - Wikidata - awgldk - TriplyDB

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

http://www.wikidata.org/entity/Q33384383

about

Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia Low dose cytarabine monotherapy for acute myeloid leukaemia Hypomethylating agents for adult patients with acute myeloid leukaemia Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Hypomethylating agents for adult patients with acute myeloid leukaemia Low dose cytarabine monotherapy for acute myeloid leukaemia Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies Oxidative stress responses and NRF2 in human leukaemia Post-remission therapy for acute myeloid leukemia Clinical Results of Hypomethylating Agents in AML Treatment Progress in acute myeloid leukemia A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.SYK regulates mTOR signaling in AML.Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.Anthocyanins from black rice (Oryza sativa) promote immune responses in leukemia through enhancing phagocytosis of macrophages in vivo.Geriatric oncology: an overview of progresses and challenges.Challenges in treating older patients with acute myeloid leukemia.Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.Acute myeloid leukemia: 2014 update on risk-stratification and management.Management of older or unfit patients with acute myeloid leukemia

P2860

Q21132375-E46191BA-75EE-4A9F-8E8A-AB70791FCD61 Q24186270-2A886334-3B24-4DFB-9A02-A655DE1F8417 Q24186284-257E178D-850C-4E58-9628-0E8BC20147F3 Q24187927-5B87B881-B4AD-48DE-9E86-36422C177CDA Q24202630-BF9A9D33-8048-4455-9EDC-3F87686F37FA Q24234645-751BFA5F-85EC-4DFE-8F8A-A966716F9CB7 Q24234680-E59BC6CC-573B-43C9-9EFC-D8D2F64314EE Q24633763-3B8CDF1C-9F1C-4F6B-9E54-B86803C9E8E5 Q26772235-FC2DC38C-46A0-41A9-BBE9-F277378F4E16 Q26864239-721FF37B-618F-494A-B31C-D12CC2ACBAC2 Q26995867-4C4DD1BA-A9EB-4833-9534-3EC394F29771 Q27022725-BC97D053-7D21-4150-8B2E-AF799BFCF888 Q27024006-E7B2697A-C6DE-459F-BE30-718C128BBD07 Q27024786-050B381E-F1AD-4F8B-B35C-97788D7B464F Q27336142-B187D6D7-B239-4475-A77F-33F8B419DEA8 Q27851545-EFA21DC7-DCD4-41DE-9D9B-E253F5848580 Q28071427-E4948878-03D4-4D54-971B-A4A9074E6520 Q30490446-969B08C0-225F-4754-B750-5ACBDE936423 Q31163049-184B9A63-6106-450F-8CE7-01F2D948E1A7 Q33396282-A92A8814-6C2F-4D95-88F1-3A5CB81677AB Q33412609-C116FE09-CC12-4609-8613-DDD3DAD5ED17 Q33424306-DBADDD34-042C-438C-B29D-98080E734669 Q33566684-469147B4-AD6A-4FAE-9BA0-6690EB179697 Q33641643-13472D53-382E-474F-A7F4-CEC4B49CCD3D Q33703046-C8ACDB19-734B-4F5F-BCF9-9413268F261D Q33841129-442E66D3-F241-42A5-BCA5-8234EA16A175 Q33846752-6AC6309D-2DD2-4E86-ACAF-580A3377E315 Q33979972-DA060740-BCB0-4062-9320-D2CF6A34849F Q33985549-5D633A9E-D971-44C0-9CAB-85919220225C Q34031134-877F9C00-71DF-44CC-AB83-1E47FD2DF03F Q34042250-FADACD40-740B-40C5-897D-A1127B1264CC Q34060237-5E91BBB7-31BD-4895-ACB0-541ACFE61E2C Q34106830-72FE67A6-2522-49A1-A89D-DDD3626FAEE6 Q34276134-1131DAEA-7CBE-4BBF-B2AB-29E9F6E99E2C Q34314177-FE3F1821-CBE6-41CB-874A-9C9811C7E395 Q34409299-3C9102C0-7601-422D-BD8B-2D493A229DCE Q34428550-10C615D0-6F03-42BC-B5BA-ECC275D139BB Q34507306-8D24C832-AF36-4509-9C21-09EF3B10626F Q34665691-C02F48D5-9682-481A-ACB6-0465918D70BF Q34893307-3957246E-D8AE-40FA-B9B1-6EA959B3C8C1

P2860

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

http://www.wikidata.org/entity/Q33384383

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@ast

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@en

type

label

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@ast

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@en

prefLabel

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@ast

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@en

P1433

Q33384383-A3995C18-CCF2-4A77-B01B-AC4448E5694E

P1476

Q33384383-26A90F0C-7E5F-4A55-88AF-D0C5FC9F9896

P2093

Q33384383-0840D0EE-F561-4FCA-B7CB-F0B39C80A745

Q33384383-092C443C-D841-49D1-BCDF-B7B983E2428F

Q33384383-3315CBA0-1135-42CF-9EA4-04BECE03E166

Q33384383-5ED4FABC-EEF4-49E0-AD1A-E4BCD80BFF17

Q33384383-6A01420B-E6B6-4AD9-85E8-D9F2E73565C5

Q33384383-6AD3AB7A-731E-41B2-A97F-71B333388E7C

Q33384383-D7940F1B-B171-4469-93CD-2277243E9C54

Q33384383-E5D538A1-C274-4FAE-8727-B270B7024CCB

P304

Q33384383-C03E7A8C-B5B5-42FC-B791-649C21F0AA49

P31

Q33384383-18BD6DD9-AC0B-402D-A82C-D2BDCA1593DA

P356

Q33384383-ACE85A7E-BDDD-4905-99C7-BEC3CC985ABE

P407

Q33384383-E821EA55-102E-42BB-ABC1-93EF3AEE0CE0

P433

Q33384383-420AC325-F4B1-4920-B2EB-681FD8A67EF0

P478

Q33384383-64273AA7-192E-4EE4-BEAF-BA63088C2154

P50

Q33384383-5AFBBC50-905C-4491-8A83-6083C994778A

Q33384383-6E7C7810-56EB-4C64-A01D-9C9112E31921

P577

Q33384383-ED6C7CD7-A84D-41BD-B295-DB0DF1EBE58B

P5875

Q33384383-736DAA6A-056E-40EA-8EF1-420319C60D93

P698

Q33384383-D12B9D67-4F32-47F6-A385-D454CDCB045C

P921

Q33384383-3665E25C-8E1D-4FD1-939A-83707E3B336C

Q33384383-712B15C6-3183-4D44-940F-7502318EE223

P356

BLOOD-2008-07-172007

P1433

P1476

Age and acute myeloid leukemia ...... edish Acute Leukemia Registry.

@en

P2093

Asa Derolf

http://www.w3.org/2001/XMLSchema#string

Dick Stockelberg

http://www.w3.org/2001/XMLSchema#string

Gunnar Juliusson

http://www.w3.org/2001/XMLSchema#string

Lars Möllgård

http://www.w3.org/2001/XMLSchema#string

Martin Höglund

http://www.w3.org/2001/XMLSchema#string

Petar Antunovic

http://www.w3.org/2001/XMLSchema#string

Sören Lehmann

http://www.w3.org/2001/XMLSchema#string

Ulf Tidefelt

http://www.w3.org/2001/XMLSchema#string

P304

4179-4187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-07-172007

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Lars Möllgård

P577

2008-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23472839

http://www.w3.org/2001/XMLSchema#string

P698

19008455

http://www.w3.org/2001/XMLSchema#string

P921